#USA #New Jersey #Novo Nordisk #Hemophilia #Denecimig

Novo Nordisk Presents New Hemophilia Data at ISTH Congress 2026

Novo Nordisk is set to present groundbreaking data related to its hemophilia treatment portfolio at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Congress, scheduled for July 11-15, 2026, in Paris, France. The presentation will highlight the findings from the phase 3 FRONTIER4 study, focusing on the investigational medication denecimig, also known as Mim8, which is a bispecific antibody designed to mimic Factor VIIIa in bleeding disorders.

The aim of the FRONTIER4 study is to evaluate the long-term efficacy and safety of denecimig across various dosing regimens—once-monthly, once-every-two-weeks, and once-weekly prophylaxis. This extensive research encompasses a wide demographic, including pediatric, adolescent, and adult hemophilia A patients, irrespective of the presence of inhibitors.

Martin Holst Lange, Novo Nordisk's Chief Scientific Officer, emphasized the necessity of addressing the diverse experiences of individuals managing hemophilia. He stated, "Everyone's experience with hemophilia is different, and we have a deep responsibility to meet the real-world needs of the community. For over 45 years, we've listened to the lived experiences of patients and continue to innovate scientifically to improve care."

In addition to denecimig, Novo Nordisk's presentations at the ISTH Congress will feature data from the explorer10 study. This research focuses on the safety and efficacy of concizumab—a treatment option for children under 12 years with hemophilia A or B and inhibitors. However, it is important to note that concizumab's use in this demographic is still investigational and not yet approved for general use.

Summary of Presentations

Novo Nordisk's involvement in the conference will include multiple oral and poster presentations. Some of the highlights include:
1. Oral Presentation of the interim results from the FRONTIER4 study discussing denecimig prophylaxis in adults and adolescents.
2. Oral Presentation of denecimig's efficacy and safety results in children with hemophilia A.
3. Poster Presentation regarding patient-reported outcomes from the long-term extension of the FRONTIER4 study.
4. Poster Presentation on how denecimig restores thrombin generation in hemophilia A patients.
5. Assessments of denecimig's impact in different hemophilia subtypes and dosing strategies, along with insights into parental and physician preferences regarding hemophilia treatment.

These studies highlight the commitment of Novo Nordisk to develop patient-centric approaches to treatment and address the unique needs within the hemophilia community. As hemophilia remains a rare but significant condition affecting over a million men globally, innovations like denecimig aim to enhance treatment outcomes and improve quality of life for patients.

The development of denecimig is also pivotal, as it has previously undergone an investigational new drug application and is currently waiting for review by the US FDA. The data presented at the ISTH Congress will be accessible on the official ISTH website, providing a broader understanding of the advancements in hemophilia treatments.

Given the critical nature of effectively managing hemophilia and the complexities involved with inhibitors, Novo Nordisk's ongoing dedication to research can forge pathways for better therapeutic choices and significantly impact patient care in the future. The insights shared at the Congress will undoubtedly resonate within the medical community, spurring ongoing discussions on how best to support those living with these blood disorders.

For further updates on Novo Nordisk's presentations, attendees are encouraged to stay engaged during the ISTH Congress and leverage the discussions to influence future research directions. Together, by focusing on innovative solutions tailored to individual patient needs, we can continue to advance care in this challenging medical field.